GlassScriptPhysician profile
Brian W King
NPI 1144328402
$1,211.13
in general payments reported to CMS, 2019-2025
13 companies · $49.70 in 2025
The $49.70 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.31 · 2020: $23.06 · 2021: $210 · 2022: $437 · 2023: $388 · 2024: $87.80 · 2025: $49.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $383.30 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $206.85 | 2021-2025 | Gattex, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.12 | 2021-2024 | Xifaxan |
| Janssen Biotech, INC. | $126.02 | 2021-2024 | Stelara |
| Ironwood Pharmaceuticals, INC | $53.22 | 2022-2023 | Linzess |
| Merck Sharp & Dohme LLC | $42.61 | 2021-2022 | |
| Boston Scientific Corporation | $42.54 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $42.37 | 2024 | |
| Genzyme Corporation | $28.27 | 2022 | |
| Solventum Corporation | $23.56 | 2025 | Promogran Prisma, Activ.A.C., Prevena |
| Bard Peripheral Vascular, INC. | $23.06 | 2020 | |
| Misonix INC | $19.32 | 2021 | |
| Ardelyx, INC. | $18.89 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.